Navigation Links
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Date:7/24/2009

Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-l
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
2. OncoGenex Pharmaceuticals Added to Russell Indexes
3. OncoGenex Pharmaceuticals Files Shelf Registration Statement
4. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
7. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
8. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
9. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN DIEGO AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose ... "Company") today reported financial results for the three months ... Unless specified otherwise, all amounts are in Canadian dollars. ... changed its fiscal year end from May 31 to ... current interim period being reported is for the three ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... addition of the "Separation Systems Market ... Macromolecules which include protein, RNA, ... are broken into smaller molecules, during production ... requires various advanced systems like centrifugation, liquid ...
(Date:5/5/2015)... , May 5, 2015 Reprints Desk, Inc., ... providing on-demand access to scientific, technical and medical (STM) ... the Association of Southeastern Research Libraries (ASERL) . ... libraries located across 11 southeastern states. Founded in 1956, ... collaborative programs to address the continually changing needs of ...
(Date:5/5/2015)... , May 05, 2015 Research and ... the addition of the "Clinical Laboratory, Molecular ... Forecast 2015 to 2019 - Global Version" ... developments especially in the area of molecular diagnostics ... growing and evolving world market that is moving ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... 6, 2011 AlloSource, ( www.allosource.org ) ... soft-tissue allografts for use in surgical procedures around the ... by the Denver Business Journal,s inaugural awards ... costs and diminishing employee benefits, the Denver Business ...
... (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it has ... by the end of the quarter, with 17 sites ... and active where patients can enroll in the Company,s ... multiforme (GBM), the most lethal form of brain cancer. ...
... ProteinSimple today announced the launch of the ... of protein-based therapeutics. The iCE3 platform will be ... 9-13, 2011, at Amelia Island, FL. ... closely. Imaged capillary electrophoresis (iCE) systems detect subtle ...
Cached Biology Technology:AlloSource Named One of Denver's Healthiest Employers 2AlloSource Named One of Denver's Healthiest Employers 3NORTHWEST BIO Announces Positive Third Quarter Progress 2NORTHWEST BIO Announces Positive Third Quarter Progress 3NORTHWEST BIO Announces Positive Third Quarter Progress 4ProteinSimple Launches New System for Protein Biologics 2
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Jolla- Salk Institute scientist Ronald Evans has been selected ... in Medicine, Israel,s highest award for achievements benefiting mankind. ... for his discovery of the gene super-family encoding nuclear ... class of receptors. Evans, professor and head of ...
... (Jan. 18, 2012) The National Eye Institute has ... subsidiary of Mass. Eye and Ear, a five year-grant ... of eye allergies (NEI Grant Number 1R01EY021798-01A1). Daniel ... the project formally entitled "Cellular and Molecular Mechanisms that ...
... Ind. -- An international team of microbiologists led by Indiana ... one that occurs at a single end or pole of ... axis of the cell -- that could have implications in ... past detailed studies of rod-shaped bacteria such as Escherichia ...
Cached Biology News:Salk scientist Ronald M. Evans wins 2012 Wolf Prize in Medicine 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 3
... disposable microfiltration devices for the fast and reliable ... l to 500 l. They can be used ... tubes. Product Features: High-flux Polyethersulphonemembrane ... hold up volume ( Fast and reproducible performance ...
... Workstation fully automates pharmaceutical sample preparation ... sample transfer, mixing and dilutions. Capabilities ... detection. The Prelude performs these functions ... Part 11. The Prelude performs ...
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... (or medium binding) polystyrene surface is ... through passive interactions,• Is suitable primarily ... such as antibodies, that have large ... the surface,• Binding capacity of approximately ...
Biology Products: